These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35753395)

  • 1. Characteristics and management of children with Clostridioides difficile infection at a tertiary pediatric hospital in China.
    Li X; Xiao F; Li Y; Hu H; Xiao Y; Xu Q; Li D; Yu G; Wang Y; Zhang T
    Braz J Infect Dis; 2022; 26(4):102380. PubMed ID: 35753395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
    Minkoff NZ; Aslam S; Medina M; Tanner-Smith EE; Zackular JP; Acra S; Nicholson MR; Imdad A
    Cochrane Database Syst Rev; 2023 Apr; 4(4):CD013871. PubMed ID: 37096495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.
    Rao K; Zhao Q; Bell J; Krishnan J; Henig O; Daniel J; Sawaya K; Albin O; Mills JP; Petty LA; Gregg K; Kaul D; Malani AN; Pogue J; Kaye KS
    Clin Infect Dis; 2024 Feb; 78(2):277-282. PubMed ID: 37797310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with concurrent ulcerative colitis.
    Porcari S; Severino A; Rondinella D; Bibbò S; Quaranta G; Masucci L; Maida M; Scaldaferri F; Sanguinetti M; Gasbarrini A; Cammarota G; Ianiro G
    J Autoimmun; 2023 Dec; 141():103033. PubMed ID: 37085337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
    Okhuysen PC; Ramesh MS; Louie T; Kiknadze N; Torre-Cisneros J; de Oliveira CM; Van Steenkiste C; Stychneuskaya A; Garey KW; Garcia-Diaz J; Li J; Duperchy E; Chang BY; Sukbuntherng J; Montoya JG; Styles L; Clow F; James D; Dubberke ER; Wilcox M
    Clin Infect Dis; 2024 Jun; 78(6):1462-1472. PubMed ID: 38305378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).
    Bouza E; Aguado JM; Alcalá L; Almirante B; Alonso-Fernández P; Borges M; Cobo J; Guardiola J; Horcajada JP; Maseda E; Mensa J; Merchante N; Muñoz P; Pérez Sáenz JL; Pujol M; Reigadas E; Salavert M; Barberán J
    Rev Esp Quimioter; 2020 Apr; 33(2):151-175. PubMed ID: 32080996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An insight into
    Thabit AK; Aljedaani HJ; Alghamdi RH; Badahdah RM; Lashkar MO; Alnajjar A
    Expert Rev Gastroenterol Hepatol; 2023; 17(8):805-810. PubMed ID: 37480286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clostridioides difficile associated peritonitis in peritoneal dialysis patients - a case series based review of an under-recognized entity with therapeutic challenges.
    Shah KJ; Cherabuddi K; Pressly KB; Wright KL; Shukla A
    BMC Nephrol; 2020 Mar; 21(1):76. PubMed ID: 32131755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors and outcomes of Clostridium difficile infection in hospitalized patients.
    Lee HY; Hsiao HL; Chia CY; Cheng CW; Tsai TC; Deng ST; Chen CL; Chiu CH
    Biomed J; 2019 Apr; 42(2):99-106. PubMed ID: 31130254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of oral vancomycin treatment duration on rate of
    Kwiatkowski D; Marsh K; Katz A; Papadopoulos J; So J; Major VJ; Sommer PM; Hochman S; Dubrovskaya Y; Arnouk S
    Infect Control Hosp Epidemiol; 2024 Jun; 45(6):717-725. PubMed ID: 38288606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of
    Hernando-Gozalo M; Rescalvo-Casas C; Seijas-Pereda L; Cuadros-González J; Pérez-Tanoira R
    Heliyon; 2024 May; 10(10):e30742. PubMed ID: 38803946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clostridioides difficile Infection in Hospitalized Pediatric Patients: Comparisons of Epidemiology, Testing, and Treatment from 2013 to 2019.
    Edwards PT; Thurm CW; Hall M; Busing JD; Kahn SA; Kellermayer R; Kociolek LK; Oliva-Hemker MM; Sammons JS; Weatherly M; Edwards KM; Nicholson MR
    J Pediatr; 2023 Jan; 252():111-116.e1. PubMed ID: 36027981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Look What the Cat Dragged in! Recurrent Clostridioides difficile from a Household Cat.
    Garza MA; Thomas B; Saleh A; Nabbout L; Quigley EMM; Mathur N
    Am J Case Rep; 2023 Oct; 24():e940923. PubMed ID: 37885171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of hospital-onset Clostridioides difficile infection in children with antibiotic-associated diarrhea.
    Polat M; Tapısız A; Demirdağ TB; Yayla BC; Kara SS; Tezer H; Belet N; Çırak MY
    Am J Infect Control; 2023 Aug; 51(8):879-883. PubMed ID: 36535316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015 - 2019: the RECUR Germany study.
    Tricotel A; Antunes A; Wilk A; Dombrowski S; Rinta-Kokko H; Andersson FL; Ghosh S
    BMC Infect Dis; 2024 Mar; 24(1):357. PubMed ID: 38539166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal Microbiota, Live-jslm for the Prevention of Recurrent Clostridioides difficile Infection : Subgroup Analysis of PUNCH CD2 and PUNCH CD3.
    Feuerstadt P; Crawford CV; Tan X; Pokhilko V; Bancke L; Ng S; Guthmueller B; Bidell MR; Tillotson G; Johnson S; Skinner AM
    J Clin Gastroenterol; 2024 Sep; 58(8):818-824. PubMed ID: 38019088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective treatment of Clostridioides difficile infection improves survival and affects graft-versus-host disease: a multicenter study by the Polish Adult Leukemia Group.
    Piekarska A; Sadowska-Klasa A; Mensah-Glanowska P; Sobczyk-Kruszelnicka M; Drozd-Sokołowska J; Waszczuk-Gajda A; Kujawska J; Wilk M; Tomaszewska A; Zaucha JM; Giebel S; Gil L
    Sci Rep; 2024 Mar; 14(1):5947. PubMed ID: 38467719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies.
    Berry P; Khanna S
    BioDrugs; 2023 Nov; 37(6):757-773. PubMed ID: 37493938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for Recurrent Clostridioides Difficile Infection in Children.
    Lee P; Nemati K; Silver EJ; Cacace J; Goldman DL
    Hosp Pediatr; 2023 Nov; 13(11):1010-1017. PubMed ID: 37877183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient.
    Lo Porto D; Mularoni A; Castagnola E; Saffioti C
    Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14159. PubMed ID: 37787395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.